See more : Midway Limited (MWY.AX) Income Statement Analysis – Financial Results
Complete financial analysis of CannaPharmaRX, Inc. (CPMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CannaPharmaRX, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Tokio Marine Holdings, Inc. (TKOMY) Income Statement Analysis – Financial Results
- Papaya Growth Opportunity Corp. I (PPYAW) Income Statement Analysis – Financial Results
- TruCap Finance Limited (TRU.BO) Income Statement Analysis – Financial Results
- Exor N.V. (EXXRF) Income Statement Analysis – Financial Results
- Rexel S.A. (RXL.PA) Income Statement Analysis – Financial Results
CannaPharmaRX, Inc. (CPMD)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cannapharmarx.com
About CannaPharmaRX, Inc.
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 620.00K | 0.00 |
| Cost of Revenue | 65.56K | 294.93K | 14.36K | 128.51K | 129.04K | 0.00 | 0.00 | 0.00 | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 490.00K | 0.00 |
| Gross Profit | -65.56K | -294.93K | -14.36K | -128.51K | -129.04K | 0.00 | 0.00 | 0.00 | -12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 130.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.97% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 589.78K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 0.00 |
| General & Administrative | 1.04M | 4.91M | 2.61M | 4.51M | 2.85M | 532.77K | 6.63K | 1.00M | 11.06M | 1.44M | 80.31K | 89.57K | 97.10K | 91.39K | 93.56K | 200.33K | 111.78K | 0.00 | 2.93M | 10.00K |
| Selling & Marketing | 243.17K | 300.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.28M | 4.91M | 2.61M | 4.51M | 2.85M | 532.77K | 6.63K | 1.00M | 11.06M | 1.44M | 80.31K | 89.57K | 97.10K | 91.39K | 93.56K | 200.33K | 111.78K | 76.12K | 2.93M | 10.00K |
| Other Expenses | 233.79K | 402.39K | 2.71K | 128.51K | 129.04K | 63.00 | 0.00 | 4.06K | 399.03K | 2.53M | 0.00 | 0.00 | 0.00 | -1.09M | 227.48K | 0.00 | 7.01M | -87.13K | 880.00K | 0.00 |
| Operating Expenses | 1.58M | 5.21M | 2.62M | 4.64M | 2.98M | 532.77K | 6.63K | 1.00M | 11.46M | 2.03M | 80.31K | 89.57K | 97.10K | -585.60K | 321.04K | 200.33K | 7.12M | -11.01K | 4.40M | 10.00K |
| Cost & Expenses | 1.58M | 5.21M | 2.62M | 4.64M | 2.98M | 532.77K | 6.63K | 1.00M | 11.46M | 2.03M | 80.31K | 89.57K | 97.10K | -585.60K | 321.04K | 200.33K | 7.12M | -11.01K | 4.89M | 10.00K |
| Interest Income | 0.00 | 2.29K | 1.51K | 2.29K | 4.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.70M | 2.29M | 1.51M | 2.29M | 4.47M | 2.14M | 0.00 | 423.00 | 2.72K | 3.95K | 14.10K | 8.50K | 2.56K | 10.20K | 4.87K | 1.26K | 4.25K | 1.40K | -460.00K | -30.00K |
| Depreciation & Amortization | 127.85K | 294.93K | 2.71K | 128.51K | 129.04K | 532.77K | 6.63K | 12.03K | 12.03K | 3.02K | 0.00 | 0.00 | 0.00 | 0.00 | -207.30K | 0.00 | -7.23M | -87.13K | 990.00K | -60.00K |
| EBITDA | -1.45M | -4.91M | -2.61M | -17.47M | -2.85M | -954.26K | -6.63K | -992.86K | -11.64M | -3.97M | -80.31K | -89.57K | -97.10K | 585.60K | -93.56K | -200.33K | -14.35M | -76.12K | -3.27M | -70.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -680.65% | 0.00% |
| Operating Income | -1.58M | -5.21M | -2.99M | -14.49M | -15.98M | -954.32K | -6.63K | -1.00M | -11.46M | -3.97M | -80.31K | -89.57K | -97.10K | 585.60K | 113.74K | -200.33K | -7.12M | 11.01K | -4.27M | -10.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -688.71% | 0.00% |
| Total Other Income/Expenses | 5.27M | -3.32M | -5.84M | -5.40M | -4.47M | -2.14M | 0.00 | 3.64K | -90.47K | -1.97M | -14.10K | -8.50K | -2.56K | -10.20K | -4.88K | -1.26K | 14.23M | -1.40K | -480.00K | -30.00K |
| Income Before Tax | 3.69M | -8.53M | -8.83M | -19.89M | -20.45M | -3.09M | -6.63K | -1.00M | -11.74M | -3.98M | -94.41K | -98.07K | -99.66K | 575.40K | 108.86K | -201.59K | 7.11M | 9.61K | -4.75M | -40.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -766.13% | 0.00% |
| Income Tax Expense | 0.00 | 2.69M | 1.51M | 2.29M | 4.47M | 2.14M | -6.64K | 423.00 | 2.72K | 1.95M | 0.00 | 0.00 | 0.00 | 0.00 | 212.18K | 0.00 | -7.00M | 88.54K | -940.00K | 0.00 |
| Net Income | 3.69M | -8.53M | -10.34M | -22.18M | -24.92M | -3.09M | -6.63K | -1.00M | -11.74M | -3.98M | -94.41K | -98.07K | -99.66K | 575.40K | 108.86K | -201.59K | 7.11M | 9.61K | -4.75M | -40.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -766.13% | 0.00% |
| EPS | 0.01 | -0.04 | -0.14 | -0.55 | -0.80 | -0.17 | 0.00 | -0.06 | -0.77 | -0.36 | -0.04 | -0.04 | -0.04 | 0.24 | 0.05 | -0.09 | 3.45 | 0.01 | -1.54 | -0.02 |
| EPS Diluted | 0.01 | -0.04 | -0.14 | -0.55 | -0.80 | -0.17 | 0.00 | -0.06 | -0.77 | -0.36 | -0.04 | -0.04 | -0.04 | 0.24 | 0.05 | -0.09 | 3.45 | 0.01 | -1.54 | -0.02 |
| Weighted Avg Shares Out | 308.94M | 211.04M | 74.69M | 40.70M | 31.17M | 17.96M | 17.96M | 17.96M | 15.34M | 11.07M | 2.38M | 2.38M | 2.38M | 2.36M | 2.36M | 2.29M | 2.06M | 831.86K | 3.08M | 2.08M |
| Weighted Avg Shares Out (Dil) | 308.94M | 211.04M | 74.69M | 40.70M | 31.17M | 17.96M | 17.96M | 17.96M | 15.34M | 11.07M | 2.38M | 2.38M | 2.38M | 2.36M | 2.36M | 2.29M | 2.06M | 831.86K | 3.08M | 2.08M |
CannapharmaRx to Complete Additional Shipment in November
CALGARY, AB / ACCESSWIRE / November 5, 2024 / CannaPharmaRX, Inc. (OTC PINK:CPMD), a future leader in cutting-edge, highly efficient cannabis production, is pleased to announce continued progress at its Cremona, Alberta facility, where cannabis cultivation remains on track according...
CannaPharmaRx Receives Multiple Purchase Orders and Begins Delivery of Product
CALGARY, AB / ACCESSWIRE / August 15, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has received three purchase orders for cannabis, for a total of 600KG, from...
Q1 2024 Financial Results
CannaPharmaRx Announces Q1 2024 Financial Results Showcasing Commencement of Revenue CALGARY, AB / ACCESSWIRE / June 28, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it filed its first...
CORRECTION FROM SOURCE: CannaPharmaRx to Host Investor Conference Call
CannaPharmaRx to Host Investor Conference Call - Tuesday May 21st, 2024 This updates the previous Press Release that had an incorrect date includedCALGARY, AB / ACCESSWIRE / May 20, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern,...
CannaPharmaRx to Host Investor Conference Call
CALGARY, AB / ACCESSWIRE / May 20, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it will hold an investor conference call on Wednesday, May 21, 2024, at 1PM...
CannapharmaRx Pays Off Convertible Notes
CALGARY, AB / ACCESSWIRE / April 2, 2024 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has extinguished convertible notes on the company. This transaction will avoid potential dilution...
CannapharmaRx Receives First Purchase Order and Begins Shipment of Product
CannapharmaRx products have been approved for sale in multiple countries worldwide CALGARY, AB / ACCESSWIRE / March 14, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has received...
CannaPharmaRx Completes First Harvests
CALGARY, AB / ACCESSWIRE / March 12, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has completed its first five grows and harvests that are ready for sale....
CannaPharmaRx to Hold Investor Conference Call
CALGARY, AB / ACCESSWIRE / March 7, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it will hold an investor conference call on Tuesday, March19, 2024 at 2PM Eastern...
CannaPharmaRx Executes Multi-Year Supply Agreement with ICAN to Create Distribution Network in the Latin Americas
CALGARY, AB / ACCESSWIRE / March 5, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that the company finalized a supply agreement with ICAN Green S.A. de C.V ("ICAN"), a...
Source: https://incomestatements.info
Category: Stock Reports